EIF4E3: A Potential Drug Target and Biomarker (G317649)

Target Name: EIF4E3

NCBI ID: G317649

EIF4E3

EIF4E3: A Potential Drug Target and Biomarker

EIF4E3, also known as OTTHUMP00000213498, is a protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a member of the EIF4 family, which includes several similar proteins that play a critical role in the regulation of cell survival and proliferation. The EIF4E3 protein has been identified as a potential drug target and biomarker, with several studies suggesting that it may be involved in a variety of biological processes, including neurodegenerative diseases, cancer, and autoimmune disorders.

Potential Drug Target

One of the most promising aspects of EIF4E3 as a drug target is its involvement in the regulation of apoptosis, or cell death. EIF4E3 has been shown to play a role in the production and execution of programmed cell death, which is a natural and essential process that helps remove damaged or dysfunctional cells from the body.

Several studies have suggested that EIF4E3 may be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells, and are often associated with significant disability and quality of life. By targeting EIF4E3, researchers may be able to develop new treatments that can slow down or reverse the progression of these diseases.

In addition to its potential role in neurodegenerative diseases, EIF4E3 has also been shown to be involved in the regulation of cancer cell survival. Several studies have suggested that EIF4E3 may be a useful target for cancer treatments, as it has been shown to promote the growth and survival of cancer cells.

Potential Biomarker

EIF4E3 has also been identified as a potential biomarker for several types of cancer, including breast, lung, and ovarian cancer. This is because the expression of EIF4E3 has been shown to be associated with the development and progression of these cancers.

One of the key advantages of using EIF4E3 as a biomarker for cancer is its potential to be used in non-invasive diagnostic tests. Unlike many other biomarkers, which require the removal of a sample of the cancer cells, EIF4E3 can be used to detect the presence of the protein in the cells themselves, which could make it a more convenient and less invasive diagnostic tool.

In addition to its potential use as a biomarker for cancer, EIF4E3 has also been suggested as a potential target for other types of diseases, including autoimmune disorders and chronic obstructive pulmonary disease (COPD).

Conclusion

EIF4E3 is a protein that has been shown to play a critical role in several important biological processes, including cell survival and proliferation. As a potential drug target and biomarker, EIF4E3 has the potential to revolutionize our understanding of these processes and may be an important area of research in the future.

Protein Name: Eukaryotic Translation Initiation Factor 4E Family Member 3

Functions: Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis. May act as an inhibitor of EIF4E1 activity (By similarity)

The "EIF4E3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF4E3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets